Skip to content
Screener

Pelthos Therapeutics PTHS Q3 2025 earnings

Reported November 13, 2025 · Before market open

Revenue$7.4MMiss by $3.0M
EPS-$5.30Miss by $4.63
Revenue estimate$10.4M
EPS estimate-$0.67

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$18.0M
EPS estimate-$2.90

Financials

Q3 2025

Income statement

See full
Revenue$7.4M—
Gross profit$5.1M—
Operating income-$15.4M-650%
Net income-$16.2M-858%

Balance sheet

See full
Cash & equivalents$14.2M+1,032%
Total debt$2.8M—
Total equity$58.3M+4,179%
Total assets$126.4M+5,808%

Cash flow

See full
Operating cash flow-$15.3M-8,487%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$85.9M—
Enterprise value$74.55M—
P/S11.6×—

Profitability

See full
Gross margin68.7%—
Operating margin-300.4%—
Net margin-318.4%—

Returns & leverage

See full
Debt / equity0×—
Current ratio2×+1.4×

FAQ

When did Pelthos Therapeutics report Q3 2025 earnings?
Pelthos Therapeutics (PTHS) reported Q3 2025 earnings on November 13, 2025 before market open.
What were Pelthos Therapeutics's Q3 2025 revenue and EPS?
Pelthos Therapeutics reported revenue of $7.4M and eps of $-5.30 for Q3 2025.
Did Pelthos Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $10.4M by $3.0M. EPS missed the consensus estimate of $-0.67 by $4.63.
Where can I find Pelthos Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001753926-25-001766) and the 10-Q periodic report (0001753926-25-001764) directly on SEC EDGAR. The filing index links above go to sec.gov.